[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586067":3},{"organization":4,"outcomesModule":7,"designInfo":69,"detailedDescription":72,"studyPopulation":73,"armGroups":74,"interventions":85,"overallOfficials":96,"centralContacts":101,"locations":106,"responsibleParty":125,"collaborators":68,"id":127,"slug":68,"hasResults":128,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":128,"sex":134,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":68,"studyType":140,"phases":68,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":109,"whyStopped":68,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},{"fullName":5,"class":6},"CorEvitas","NETWORK",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":68},[9],{"measure":10,"description":11,"timeFrame":12},"Major congenital malformation","An abnormality of body structure or function that is present at birth, is of prenatal origin (i.e., birth defect), has significant medical, social, or cosmetic consequences for the affected individual, and typically requires medical intervention.","Full pregnancy period (~9 months)",[14,17,21,24,27,30,34,38,42,45,49,52,56,59,62,65],{"measure":15,"description":16,"timeFrame":12},"Minor congenital malformation","An anomaly or abnormality of body structure that is present at birth, is of prenatal origin (i.e., birth defect), poses no significant health problem in the neonatal period, and tends to have limited social or cosmetic consequences for the affected individual.",{"measure":18,"description":19,"timeFrame":20},"Spontaneous abortion","An involuntary fetal loss or the expulsion of the products of conception occurring at \\\u003C20 gestational weeks.","\u003C20 gestational weeks",{"measure":22,"description":23,"timeFrame":12},"Pregnancy termination","A voluntary fetal loss or interruption of pregnancy that occurs for any reason, including but not limited to for the preservation of maternal health or because of fetal abnormalities.",{"measure":25,"description":26,"timeFrame":12},"Preeclampsia","A disorder of pregnancy associated with new-onset hypertension, which occurs most often after 20 weeks of gestation and frequently near term, and proteinuria. Or, in the absence of proteinuria, it is defined as new-onset hypertension with the new onset of any of the following:\n\n* Thrombocytopenia: platelet count \\\u003C100,000\u002FmL\n* Renal insufficiency: serum creatinine concentrations \\>1.1 mg\u002FdL or a doubling of the serum creatinine concentration in the absence of other renal disease\n* Impaired liver function: elevated blood concentrations of liver transaminases to twice the normal concentration\n* Pulmonary edema\n* New-onset headache unresponsive to medication and not accounted for by alternative diagnoses or visual symptoms",{"measure":28,"description":29,"timeFrame":12},"Eclampsia","New-onset tonic-clonic, focal, or multifocal seizures in the absence of other causative conditions such as epilepsy, cerebral arterial ischemia and infarction, intracranial hemorrhage, or drug use.",{"measure":31,"description":32,"timeFrame":33},"Stillbirth","Involuntary fetal loss occurring at ≥20 gestational weeks or, if gestational age is unknown, a fetus weighing ≥350g","≥20 gestational weeks",{"measure":35,"description":36,"timeFrame":37},"Preterm birth","A live birth occurring at \\\u003C37 gestational weeks","\u003C37 gestational weeks",{"measure":39,"description":40,"timeFrame":41},"Small for gestational age","Birth weight \\\u003C10th percentile for sex and gestational age using standard growth charts for full and preterm live-born infants.","At infant birth (up to 12 months of age)",{"measure":43,"description":44,"timeFrame":12},"Gestational diabetes","Any degree of glucose intolerance with onset or first recognition during pregnancy",{"measure":46,"description":47,"timeFrame":48},"Pregnancy induced hypertension","A disorder of pregnancy defined as a systolic blood pressure of 140 mm Hg or more or a diastolic blood pressure of 90 mm Hg or more, or both, on two occasions at least 4 hours apart after 20 weeks of gestation in a woman with previously normal blood pressure",">20 gestational weeks",{"measure":50,"description":51,"timeFrame":12},"Placental abruption","Premature separation of the placenta from its uterine attachment before the delivery of a fetus",{"measure":53,"description":54,"timeFrame":55},"Postnatal growth deficiency","Weight, length, or head circumference in \\\u003C10th percentile for sex and chronological age using standard growth charts","Up to 12 months of age",{"measure":57,"description":58,"timeFrame":55},"Infant developmental delay","Failure to achieve the developmental milestones for chronological age, as defined by the CDC.",{"measure":60,"description":61,"timeFrame":55},"Infant hospitalization","The admission of an infant to a hospital",{"measure":63,"description":64,"timeFrame":55},"Infant infections (serious or nonserious)","Infant infections that resulted in medical visit or hospitalization",{"measure":66,"description":67,"timeFrame":55},"Infant death","The death of an infant before his or her first birthday",null,{"allocation":68,"interventionModel":68,"interventionModelDescription":68,"primaryPurpose":68,"observationalModel":70,"timePerspective":71,"maskingInfo":68},"COHORT","PROSPECTIVE","Rationale and Background:\n\nInflammatory bowel disease (IBD) is a group of chronic inflammatory conditions that affect the gastrointestinal tract and can be divided into two main types: Crohn's disease (CD) and ulcerative colitis (UC). Half of the people diagnosed with IBD received their diagnosis before the age of 35 years, which coincides with the peak reproductive years for women. Studies have shown that IBD is associated with increased risk of adverse pregnancy and fetal outcomes, including preterm birth, stillbirth, and low birth weight. The CorEvitas IBD Pregnancy Registry (IBD-PR) aims to collect real-world evidence on the safety of IBD pharmacotherapies during pregnancy and the first year of infant life and provide valuable insights into the risks and safety profiles of IBD medications, enabling healthcare professionals to make more informed decisions when managing IBD in pregnant individuals.\n\nResearch Question and Objectives: Data collected through the registry may be used to address a range of research questions and objectives, including but not limited to the following:\n\nThe research question is: Is there an increased risk of adverse maternal, fetal, or infant outcomes among individuals who are exposed to IBD pharmacotherapies during pregnancy?\n\nThe primary objective of the registry is to estimate the prevalence of major congenital malformations (MCM) among pregnant individuals with IBD who are exposed to an IBD pharmacotherapy during pregnancy.\n\nThe secondary objectives of the registry are:\n\nTo estimate the prevalence of other maternal, fetal, and infant outcomes among pregnant individuals with IBD who are exposed to an IBD pharmacotherapy during pregnancy\n\nTo contextualize the prevalence of outcomes among pregnant individuals who are exposed to IBD pharmacotherapies during pregnancy and estimate the prevalence of all outcomes of interest among pregnant individuals with IBD who are not exposed to an IBD pharmacotherapy during pregnancy\n\nIf sample size permits, to estimate the risk ratio for each outcome, comparing the outcomes of pregnant individuals with IBD who are exposed to an IBD pharmacotherapy with outcomes of those who are not exposed to an IBD pharmacotherapy\n\nData collection may be used to determine pharmacotherapy-specific use with or without unexposed cohorts on an as-needed basis, as sample size allows.\n\nStudy Design: This prospective, observational cohort study is designed to estimate the prevalence of maternal, fetal, and infant outcomes among individuals with IBD who are exposed to an IBD pharmacotherapy during pregnancy. For this registry, the index date will be the date of first exposure to the IBD pharmacotherapy for the exposed cohort and the date of enrollment for the unexposed cohort. The risks of pregnancy-related outcomes, maternal outcomes, and neonatal\u002Finfant outcomes will be estimated for participants with IBD exposed and unexposed to any IBD pharmacotherapies or an IBD pharmacotherapy of interest during pregnancy.\n\nPopulation: The registry population will include two cohorts of pregnant individuals: one cohort of individuals with a diagnosis of IBD who are exposed to an IBD pharmacotherapy during pregnancy and one cohort of individuals with a diagnosis of IBD who are not exposed to IBD pharmacotherapies during pregnancy.\n\nVariables: Individuals will be considered exposed during pregnancy if at least one dose of an IBD treatment is taken during pregnancy or up to at least five times the product's half-life before conception. The primary outcome of interest is MCMs. The maternal and pregnancy secondary outcomes include minor congenital malformations, preeclampsia, eclampsia, spontaneous abortion, stillbirth, pregnancy termination, preterm birth, small for gestational age, gestational diabetes, pregnancy-induced hypertension, and placental abruption. The infant secondary outcomes during the first year of life include postnatal growth deficiency, infant developmental delay, infant hospitalization, infant infections (both serious and nonserious), and infant death. Covariates will include demographics, risk factors for the outcomes, comorbidities, concomitant medications, and predictors of treatment with an approved IBD pharmacotherapy.\n\nData Source: This registry will collect data from participants and healthcare providers involved in their care or the care of their infants via concise data collection forms at predefined timepoints during pregnancy, at pregnancy outcome, and up to 1 year of infant age.\n\nStudy Size: The registry aims to include as many pregnant individuals as possible, with no defined upper limit on enrollment in each cohort, to estimate the prevalence of the primary outcome, MCM, with meaningful confidence and precision. This approach aims to achieve adequate sample size to address additional research questions of interest, and\u002For maintain generalizability and representativeness of the registry population. Assuming a prevalence of MCM equivalent to 3% in each cohort, 1,143 and 303 live births in the analysis population of each cohort are needed to estimate the prevalence of MCM with ±1% and 2% precision, respectively.\n\nData Analysis: Participant characteristics will be summarized with descriptive statistics for each cohort. Comparative analyses will be conducted for each outcome if sample size permits. Supplementary analyses will be conducted that include pregnant individuals who were excluded from the analysis population. If sample size permits, subgroup and sensitivity analyses will be performed to examine the extent to which changes in certain methods or assumptions affect the results.\n\nMilestones: The IBD-PR is expected to launch in March 2025, and the end of data collection is planned for 30 September 2032.","Pregnant individuals across the US \\& Canada who learn of the study via nationwide advertising campaigns or via their healthcare providers",[75,80],{"label":76,"type":68,"description":77,"interventionNames":78},"IBD pharmacotherapy exposed","Individuals with a diagnosis of IBD who are exposed to an approved IBD pharmacotherapy at any time during pregnancy",[79],"Drug: Exposed to IBD pharmacotherapy during pregnancy",{"label":81,"type":68,"description":82,"interventionNames":83},"IBD pharmacotherapy unexposed","Individuals with a diagnosis of IBD who are not exposed to IBD pharmacotherapy during pregnancy",[84],"Other: Non-exposed group",[86,91],{"type":87,"name":88,"description":89,"armGroupLabels":90,"otherNames":68},"OTHER","Non-exposed group","Pregnant individuals with IBD who are not exposed to an IBD pharmacotherapy during pregnancy",[81],{"type":92,"name":93,"description":94,"armGroupLabels":95,"otherNames":68},"DRUG","Exposed to IBD pharmacotherapy during pregnancy","Pregnant individuals with IBD who are exposed to an IBD pharmacotherapy during pregnancy",[76],[97],{"name":98,"affiliation":99,"role":100},"Ronna L Chan, PhD, MPH","PPD, Part of Thermo Fisher Scientific","PRINCIPAL_INVESTIGATOR",[102],{"name":98,"role":103,"phone":104,"phoneExt":68,"email":105},"CONTACT","800-616-3791","ibd-pr@corevitas.com",[107],{"facility":108,"status":109,"city":110,"state":111,"zip":112,"country":113,"countryCode":114,"cosmosGeoPoint":115,"geoPoint":120,"contacts":121},"PPD","RECRUITING","Wilmington","North Carolina","28401","United States","US",{"type":116,"coordinates":117},"Point",[118,119],-77.94604,34.23556,{"lat":119,"lon":118},[122],{"name":123,"role":103,"phone":124,"phoneExt":68,"email":105},"CorEvitas Clinical Research Associate","1-800-616-3791",{"type":126,"investigatorFullName":68,"investigatorTitle":68,"investigatorAffiliation":68,"oldNameTitle":68,"oldOrganization":68},"SPONSOR","100586067",false,"NCT06910553","IBD Pregnancy Registry","CorEvitas Inflammatory Bowel Disease Pregnancy Registry (IBD-PR)","IBD-PR","Inclusion Criteria:\n\nExposed and unexposed cohort:\n\n* A resident of the US or Canada at enrollment\n* Currently pregnant\n* 18 to 50 years of age at enrollment\n* Physician-confirmed diagnosis of IBD (UC, CD, other and unspecified noninfective gastroenteritis and colitis \\[ICD-10 K52\\] and indeterminate colitis \\[ICD-10 K52.3\\])\n* Evidence of a personally signed and dated informed consent document or, upon waiver of written consent by the relevant institutional review board (IRB)\u002Findependent ethics committee, verbal consent, indicating that the individual (or a legally acceptable representative) has been informed of all pertinent aspects of the study\n* Authorize their HCP to provide data to the registry\n* Provide contact information (for participant and HCPs)\n\nExposed cohort only:\n\n\\- Exposed to an IBD pharmacotherapy during pregnancy\n\nExclusion Criteria:\n\nExposed and unexposed cohort:\n\n* Exposure to methotrexate during pregnancy","FEMALE","18 Years","50 Years",{"count":138,"type":139},832,"ESTIMATED","OBSERVATIONAL","Data collected through the registry may be used to address a range of research questions and objectives, including but not limited to the following:\n\nResearch question: Is there an increased risk of adverse maternal, fetal, or infant outcomes among individuals who are exposed to Inflammatory Bowel Disease (IBD) treatments during pregnancy?\n\nThe primary objective of the registry is to estimate the prevalence of major congenital malformations among pregnant individuals with IBD who are exposed to an IBD pharmacotherapy during pregnancy.\n\nThe secondary objectives of the registry are:\n\nTo estimate the prevalence of other maternal, fetal, and infant outcomes among pregnant individuals with IBD who are exposed to IBD pharmacotherapies during pregnancy.\n\nTo contextualize the prevalence of outcomes among pregnant individuals who are exposed to IBD pharmacotherapies during pregnancy and estimate the prevalence of all outcomes of interest among pregnant individuals with IBD who are not exposed to any IBD pharmacotherapies or an IBD pharmacotherapy of interest during pregnancy.\n\nIf sample size permits, to estimate the risk ratio for each outcome, comparing the outcomes of pregnant individuals with IBD who are exposed to IBD pharmacotherapy with those who are not exposed to any IBD pharmacotherapies or an IBD pharmacotherapy of interest during pregnancy.\n\nData collection may be used to determine pharmacotherapy-specific use with or without unexposed cohorts on an as-needed basis, as sample size allows.",[143],"Inflammatory Bowel Disease (IBD)",[145,146,147,148,149,150],"Pregnant","IBD","Registry","UC","Inflammatory Bowel Disease","Ulcerative Colitis","2025-04-02",{"date":153,"type":154},"2025-04-04","ACTUAL",{"date":156,"type":139},"2025-04",{"date":158,"type":139},"2032-09",{"name":5,"class":6},1]